Skip to main content
Top
Published in: Clinical Rheumatology 12/2008

01-12-2008 | Case Report

Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy

Authors: Pamela Mangat, Samuel Whittle, Les Cleland, Vidya Limaye

Published in: Clinical Rheumatology | Issue 12/2008

Login to get access

Abstract

Anti-tumour necrosis factor alpha therapy has led to significant advancement in the treatment of rheumatological disease. Rarely, anti-TNFα antagonists have been associated with vasculitis, predominantly cutaneous leukocytoclastic vasculitis. We present the first case of angiographically-confirmed digital vasculitis occurring as a late complication of etanercept therapy. Our case adds to the limited repertoire of case reports of anti-TNFα induced vasculitis and highlights the potential risk of this serious complication occurring up to several years after initiation of these agents.
Literature
1.
go back to reference Furst DE, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 66:iii2–iii22, NovPubMedCrossRef Furst DE, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 66:iii2–iii22, NovPubMedCrossRef
2.
go back to reference Lin J, Ziring D, Desai S et al (2008) TNFα blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126:13–30PubMedCrossRef Lin J, Ziring D, Desai S et al (2008) TNFα blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126:13–30PubMedCrossRef
3.
go back to reference Marcoux BS, Bandt MD (2006) Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Jt Bone Spine 73:710–713CrossRef Marcoux BS, Bandt MD (2006) Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Jt Bone Spine 73:710–713CrossRef
4.
go back to reference Mohan N, Edwards ET, Cupps TR (2004) Leukocytoclastic vasculitis associated with tumour necrosis factor-α blocking agents. J Rheumatol 31(10):1955–1958PubMed Mohan N, Edwards ET, Cupps TR (2004) Leukocytoclastic vasculitis associated with tumour necrosis factor-α blocking agents. J Rheumatol 31(10):1955–1958PubMed
5.
go back to reference Stokes MB, Foster K, Markowitz GS et al (2005) Development of glomerulonephritis during anti-TNFα therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400–1406PubMedCrossRef Stokes MB, Foster K, Markowitz GS et al (2005) Development of glomerulonephritis during anti-TNFα therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400–1406PubMedCrossRef
6.
go back to reference Stubgen JP (2008) Tumour necrosis factor-α antagonists and neuropathy. Muscle and Nerve 37(3):281–292, MarchPubMedCrossRef Stubgen JP (2008) Tumour necrosis factor-α antagonists and neuropathy. Muscle and Nerve 37(3):281–292, MarchPubMedCrossRef
7.
go back to reference Livermore PA, Murray KJ (2002) Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology 41:1450–1452PubMedCrossRef Livermore PA, Murray KJ (2002) Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology 41:1450–1452PubMedCrossRef
8.
go back to reference Desai SB, Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20(4):757–790PubMedCrossRef Desai SB, Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20(4):757–790PubMedCrossRef
Metadata
Title
Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy
Authors
Pamela Mangat
Samuel Whittle
Les Cleland
Vidya Limaye
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 12/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1015-9

Other articles of this Issue 12/2008

Clinical Rheumatology 12/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.